Immune Checkpoint Inhibitors in Cancer

  • ID: 4519534
  • Book
  • 270 Pages
  • Elsevier Health Science
1 of 4

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 4
1. Tumor Immunology

2. Melanoma and Other Skin Cancers

3. Thoracic Malignancies

4. Gastrointestinal, Hepatobiliary, and Pancreatic Malignancies

5. Cancers of the Head and Neck

6. Urologic Malignancies

7. Gynecologic Malignancies

8. Breast Cancer

9. Hematologic Malignancies

10. Pediatric Malignancies

11. Toxicities Associated with Immune Checkpoint Inhibitors

12. Future of Immune Checkpoint Inhibitors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Ito, Fumito Associate Professor of Oncology, Department of Surgical Oncology, Member, Center for Immunotherapy, Roswell Park Cancer Institute; Associate Professor of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York.

Dr. Fumito Ito is Associate Professor of Oncology, Department of Surgical Oncology and a member of the Center for Immunotherapy at Roswell Park Cancer Institute, as well as Associate Professor of Surgery at Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York.
Ernstoff, Marc Professor and Chair, Department of Medicine, Senior Vice President for Clinical Investigation, The Katherine Anne Gioia Chair of Medicine, Roswell Park Cancer Institute; Chief, Division of Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffaclo, New York.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll